Orforglipron
Extensively studiedOral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction
Molecular & research data
- Sequence
- Not applicable - synthetic small molecule
- Molecular weight
- 882.974 Da
- Half-life
- 25-68 hours
- Primary targets
- glp1-receptor
- Routes (research)
- Oral
- Storage
- Room temperature 15-30°C; no refrigeration needed
Overview
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Mechanism of action
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Key research findings
- Significant weight loss (up to 12.4% at 72 weeks)
- Robust diabetes control (HbA1c reduction 1.3-1.6%)
- Once-daily oral tablet format
- No refrigeration or food restrictions required
- Reduced cardiovascular risk markers
Research applications
Weight Loss
- Obesity Without Diabetes — ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
- Obesity With Type 2 Diabetes — ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- Cardiometabolic Risk Reduction — Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
- Prediabetes Prevention — 91% achieved near-normal blood sugar levels versus 42% with placebo.
Type 2 Diabetes
- Type 2 Diabetes Management — ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
- Insulin Resistance Improvement — Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Orforglipron FAQ
How does orforglipron compare to semaglutide for weight loss?+
Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.
Why does orforglipron cause more diarrhea than other GLP-1s?+
The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.
Can I take orforglipron with food, or does it need an empty stomach?+
Orforglipron can be taken with or without food and at any time of day, according to the protocols. This flexibility is a key advantage over some other GLP-1 formulations. You don't need to plan around meals for administration.
Is orforglipron safe if I have a family history of thyroid cancer?+
No. Orforglipron is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Like other GLP-1 agonists, there's a theoretical risk of thyroid C-cell tumors. Discuss your family history thoroughly with your healthcare provider before starting.
References
Related peptides
Semaglutide
FDA-approvedFDA-approved GLP-1 receptor agonist
Semaglutide is an FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management, engineered with fatty-acid acylation for a once-weekly half-life.
Tirzepatide
FDA-approvedFDA-approved dual GIP/GLP-1 receptor agonist
Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management, producing larger average weight reduction than GLP-1-only agents in trials.
BPC-157
PreclinicalPentadecapeptide studied for tissue repair
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice, studied extensively in animal models for accelerated healing of tendon, ligament, muscle, and gut tissue.
Last reviewed: 2026-06-26. Information is provided for research and educational reference only — see our disclaimer.